Literature DB >> 19197195

Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6-month mortality in cirrhotic patients.

Jérôme Boursier1, Elodie Cesbron, Anne-Laure Tropet, Christophe Pilette.   

Abstract

BACKGROUND/GOALS: Superiority of the model for end-stage liver disease (MELD) over the Child-Pugh score for the prediction of outcome in patients with chronic liver disease is still debated. The main objective of this prospective study was to evaluate the accuracy of the Child-Pugh score, the MELD, and the new score, MELD-Na, combining MELD and serum sodium (Na), for the prediction of 6-month mortality in cirrhotic patients. STUDY: In all, 308 consecutive cirrhotic patients were included. Child-Pugh score, MELD, and MELD-Na were calculated at the inclusion.
RESULTS: In all, 154 patients (50.0%) had decompensated cirrhosis. Forty-five patients died during the 6-month follow-up: 3 in the subgroup of compensated cirrhosis and 42 in the decompensated subgroup (1.9% vs. 27.3%, P<10(-3)). Area under the receiver operating characteristic curve for the prediction of 6-month mortality of Child-Pugh score, MELD, and MELD-Na were, respectively, in the whole population: 0.882, 0.866, and 0.887 (P=NS), and in the subgroup of decompensated cirrhosis: 0.796, 0.800, and 0.833 (P=NS). MELD-Na had the highest accuracy but the difference reached statistical significance only with the Child-Pugh score in the subgroup of patients with decompensated cirrhosis (79.9% vs. 68.0%, P=0.006). The combination of Child-Pugh score or MELD with other variables reflecting the circulatory dysfunction observed in end-stage liver disease significantly improved the accuracy of these 2 models.
CONCLUSIONS: Child-Pugh score remains a simple and effective tool for the prognostic assessment of cirrhotic patients at bedside and can still be used in clinical practice. MELD, and especially MELD-Na, should be reserved for patients with decompensated cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19197195     DOI: 10.1097/MCG.0b013e3181889468

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  25 in total

1.  MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis.

Authors:  Tobias Heye; Schu-Ren Yang; Michael Bock; Sylvia Brost; Kilian Weigand; Thomas Longerich; Hans-Ulrich Kauczor; Waldemar Hosch
Journal:  Eur Radiol       Date:  2012-02-03       Impact factor: 5.315

Review 2.  Prioritization for liver transplantation.

Authors:  Evangelos Cholongitas; Giacomo Germani; Andrew K Burroughs
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

3.  Activation of inactive hepatocytes through histone acetylation: a mechanism for functional compensation after massive loss of hepatocytes.

Authors:  Yujun Shi; Huaiqiang Sun; Ji Bao; Ping Zhou; Jie Zhang; Li Li; Hong Bu
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

4.  Proportions of acetyl-histone-positive hepatocytes indicate the functional status and prognosis of cirrhotic patients.

Authors:  Ping Zhou; Jie Xia; Yong-Jie Zhou; Jun Wan; Li Li; Ji Bao; Yu-Jun Shi; Hong Bu
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

5.  Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study.

Authors:  Maria Kalafateli; Konstantinos Zisimopoulos; Georgia Vourli; Cristina Rigamonti; John Goulis; Emanuel Manesis; Spilios Manolakopoulos; Emmanuel Tsochatzis; Aikaterini Georgiou; Georgia Diamantopoulou; Konstantinos Thomopoulos; Charalambos Gogos; Giota Touloumi; Evangelos Akriviadis; Chryssoula Lambropoulou-Karatza; Christos Triantos
Journal:  Dig Dis Sci       Date:  2017-03-01       Impact factor: 3.199

6.  Living donor liver transplantation for high model for end-stage liver disease score: What have we learned?

Authors:  Hany Dabbous; Mohammad Sakr; Sara Abdelhakam; Iman Montasser; Mohamed Bahaa; Hany Said; Mahmoud El-Meteini
Journal:  World J Hepatol       Date:  2016-08-08

7.  Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma.

Authors:  Winnie Yeo; Pei-Jer Chen; Junji Furuse; Kwang-Hyub Han; Chiun Hsu; Ho-Yeong Lim; Hanlim Moon; Shukui Qin; Ee-Min Yeoh; Sheng-Long Ye
Journal:  BMC Cancer       Date:  2010-11-10       Impact factor: 4.430

8.  Systematic review of peri-operative nutritional support for patients undergoing hepatobiliary surgery.

Authors:  Yin Liu; Xiaoyan Xue
Journal:  Hepatobiliary Surg Nutr       Date:  2015-10       Impact factor: 7.293

9.  Model for End-Stage Liver Disease score predicts mortality in critically ill cirrhotic patients.

Authors:  M Dustin Boone; Leo A Celi; Ben G Ho; Michael Pencina; Michael P Curry; Yotam Lior; Daniel Talmor; Victor Novack
Journal:  J Crit Care       Date:  2014-05-28       Impact factor: 3.425

10.  Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma.

Authors:  Hyun Seok Lee; Soo Young Park; Sung Kook Kim; Young Oh Kweon; Won Young Tak; Chang Min Cho; Seong Woo Jeon; Min Kyu Jung; Hyun Gu Park; Dong Wook Lee; So Young Choi
Journal:  Clin Mol Hepatol       Date:  2012-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.